Cefteram

Bacterial infectious diseases have long ranked high on the list of common and frequently-occurring clinical diseases. Third-generation cephalosporins have always been the core choice for anti-infective treatment due to their broad antibacterial spectrum and high stability against β-lactamase. Cefteram is a third-generation oral cephalosporin drug. Its mechanism of action is to exert bactericidal activity by inhibiting the biosynthesis of bacterial cell walls, and it has strong antibacterial effects against Streptococcus and Pneumococcus among Gram-positive bacteria, as well as Escherichia coli, Klebsiella, Haemophilus influenzae among Gram-negative bacteria. Clinically, it is mainly used to treat infectious diseases such as acute bronchitis, pneumonia, pyelonephritis, cystitis, otitis media and sinusitis caused by sensitive bacteria, and is suitable for adult and pediatric patients with mild to moderate bacterial infections. The convenience of oral administration also greatly improves the compliance of outpatient treatment.

At present, the market size of domestic oral anti-infective drugs is expanding steadily, among which third-generation oral cephalosporins account for nearly 25%. As a mature variety for clinical use, the total sales of cefteram in domestic public hospitals and retail terminals exceeded 720 million yuan in 2023, with a compound annual growth rate of 8.1% in the past 3 years. At present, 12 domestic enterprises have been approved to produce cefteram-related preparations, and the generic drug substitution rate has exceeded 75%. With the continuous release of demand for oral anti-infective drugs in the primary medical market, the market penetration rate of cefteram still has room for further improvement in the future.

The original research enterprise of cefteram is Toyama Chemical Co., Ltd. of Japan, and the original research trade name is "Meiact". The core compound patent of cefteram expired in Japan in 2006, and the compound patent in China expired in 2007. The main dosage form approved by the original research is cefteram pivoxil tablets, with specifications of 50mg and 100mg. The original research product has been included in the China Listed Drug Catalogue and is used as a reference preparation. In terms of domestic API registration, 6 enterprises have completed the registration of cefteram pivoxil APIs in CDE and obtained approval for use in marketed preparations. The domestic approved preparation types cover three categories: tablets, capsules and dry suspensions. (Data as of July 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of cefteram impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for the whole process of quality research, stability study, declaration and registration of API and preparation enterprises.